angina

(redirected from exertional angina)
Also found in: Dictionary, Medical, Encyclopedia.
Related to exertional angina: crescendo angina, variant angina, Vasospastic Angina
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for angina

any disease of the throat or fauces marked by spasmodic attacks of intense suffocative pain

a heart condition marked by paroxysms of chest pain due to reduced oxygen to the heart

References in periodicals archive ?
based Phase IIb/III study, which will be conducted in up to 100 medical centers is evaluating the safety and efficacy of Generx/AGT in patients with stable exertional angina due to coronary artery disease, who do not require immediate revascularization.
To participate in the trial, patients had to have moderate to severe exertional angina despite being on antianginal medicine.
The Circulation article, entitled "Angiogenic GENe Therapy (AGENT) Trial in Patients with Stable Angina Pectoris", describes safety and preliminary efficacy data on the use of GENERX, an adenovirus serotype 5 encoding for Fibroblast Growth Factor-4 (FGF4) for the potential treatment of stable exertional angina.
GENERX(TM), a non-surgical angiogenic gene therapy designed for the potential treatment of stable exertional angina due to coronary artery disease, is now in large-scale Phase 2b/3 trials in the United States and is expected to be in large-scale clinical trials in Europe in January 2002.
as part of the European clinical development for GENERX, Collateral's lead product candidate for the potential treatment of stable exertional angina due to coronary artery disease.
The Company's lead product candidate, GENERX(TM), a non-surgical gene therapy designed for the potential treatment of stable exertional angina due to coronary artery disease is entering large-scale Phase 2b/3 trials in both the United States and Europe and GENVASCOR(TM), Collateral's second angiogenic gene therapy is entering Phase 1/2 studies in Europe for the potential treatment of peripheral vascular disease.
GENERX, designed for the potential treatment of stable exertional angina due to coronary artery disease, is advancing to large-scale, Phase 2b/3 Pivotal trials both here in the United States and in Europe.
GENERX(TM), a non-surgical angiogenic gene therapy designed for the potential treatment of stable exertional angina due to coronary artery disease is advancing to large-scale, Phase 2b/3 Pivotal trials both here in the United States and in Europe.
Ad5-FGF4 is a non-surgical angiogenic gene therapy product candidate being developed for the treatment of patients with stable exertional angina due to coronary artery disease.
The AGENT trial evaluated the safety and anti-ischemic effects of ascending doses of Ad5FGF4 in patients with stable exertional angina.
are conducting a placebo-controlled, double-blinded Phase 1/2 study to determine the effects of increasing doses of Ad5FGF4 in patients with stable exertional angina due to coronary artery disease.